Pharma Sector

The Indian benchmark indices staged a strong recovery on May 14, 2026, driven by strong quarterly earnings, bargain buying, and improving global sentiment. Pharma, healthcare, metal, and financial stocks witnessed robust gains, while IT shares remained under pressure due to rising concerns over AI-led disruption in the outsourcing sector. Cipla, Adani Enterprises, Bharti Airtel, and Zydus Lifesciences emerged among the top trending stocks of the day.

Cipla Q4 FY26 results were mixed, with a sharp decline in profit and margins offset by strong growth in India and Africa businesses. Despite weak North America performance, investor sentiment turned positive as adjusted earnings and dividends provided stability.

Sun Pharmaceutical Industries is set to acquire Organon & Co. in a $11.75 billion all-cash deal, driving its stock up 7% on the NSE. The acquisition enhances its global footprint, strengthens its women’s health portfolio, and marks a major entry into biosimilars.

After a week packed with major triggers like the Union Budget, the Indo-US trade deal, and the RBI policy, markets now turn to assessing real impact. The coming week will focus on how the trade deal affects exports, imports, currency risks, and overall market direction, along with key inflation and global data cues.

However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.

The partnership focuses on commercializing GLP-1 (glucagon-like peptide-1) products for diabetes treatment and chronic weight management in the Middle East.

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.